Please login to the form below

Not currently logged in
Email:
Password:

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

Menarini has signed an €800m deal with Oxford BioTherapeutics to collaborate on the development of antibody-body based drugs for the treatment of several cancers.

The Italy-based pharma firm will lead the manufacturing and clinical development of five of Oxford's antibody and antibody-drug conjugate (ADC) programmes, each addressing a separate cancer indication.

Once clinical proof of concept has been achieved in each programme, Menarini would then develop and commercialise the products in Europe, CIS, Asia and Latin America, while Oxford would retain the rights in North America and Japan.

Heading up Oxford's efforts as part of the collaboration will be chief operating officer Dr Esteban Pombo-Villar, who left Novartis to join the UK-based company in May, 2012.

He was brought in to oversee the biotech's clinical development operations in Basel, Switzerland, where much of Oxford's work into antibodies is taking place.

Oxford's CEO Christian Rohlff was enthusiastic about the collaboration and what it means for the company's future.

“This creative alliance is transformational for us as it allows Oxford BioTherapeutics to participate in the clinical development and future commercialisation of our programmes while at the same time it bolsters Menarini's pipeline with a portfolio of the next generation of cancer drugs,” he said.

“We believe this innovative business framework could become the business model of choice for rapidly growing biotechnology companies seeking new ways to develop their drug pipeline effectively.”

ADCs, which comprise a cancer cell-targeting antibody that is attached to a cytotoxic drug via a linking technology, have been demonstrating promising results as a more targeted cancer therapy.

This promise has led to recent deals like that between Abbott and Seattle Genetics, which will see the partners extend their existing ADC agreement to cover several more cancers, with each programme worth up to $220m in milestone payments.

Leading the charge, however, is Roche's T-DM1, which has shown great potential in extending survival in patients with breast cancer during clinical trials and has been tipped as a future blockbuster.

30th October 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...